A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens

Trial Profile

A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Results (n=118) of exploratory analysis assessing whether incidences of irAE decreases if D with or without T is given with CT or CS, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Dec 2016 Results assessing safety and tolerability of durvalumab with or without tremelimumab (n=78) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 19 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top